Christopher E. Kelly, MD

Panelist discusses how urologists can benefit from adopting newer treatment modalities like aqua ablation for BPH, emphasizing its growing popularity, ease of learning, and efficiency in improving patient throughput, while still allowing urologists to leverage their existing skills.

Panelist discusses how hospitals benefit from adopting aqua ablation therapy by improving surgical efficiency, reducing turnover times, enabling outpatient procedures, and providing a highly effective treatment option that can enhance patient outcomes while preserving sexual function.

Panelist discusses how the ability to administer treatments robotically, regardless of prostate size, affects resource expenditures in a clinic, highlighting the need for extended recovery periods and increased use of apps to streamline patient management and reduce resource burdens.

Panelist discusses how benign prostatic hyperplasia (BPH) and its treatments impact men’s sexual health, emphasizing the importance of balancing symptom relief with sexual function preservation, and how patient concerns, along with treatment advancements like aqua ablation, have simplified decision-making in clinical practice.

Panelist discusses how clinical data from multiple studies demonstrate that aqua ablation therapy offers efficacy comparable with that of transurethral resection of the prostate (TURP) while providing superior safety, functionality, and durability benefits.

Panelist discusses how patient outcomes have evolved over time with different benign prostatic hyperplasia (BPH) treatments, highlighting improvements in ejaculation preservation, durability, and post procedure complications across various techniques.

A panelist discusses how benign prostatic hyperplasia (BPH) treatment has evolved to include a spectrum of minimally invasive and surgical interventions, ranging from emerging technologies like prostatic urethral lift (PUL) and water vapor thermal therapy (WVTT) to more established resective surgical techniques such as transurethral resection of the prostate (TURP), holmium laser enucleation (HoLEP), Aquablation, and Greenlight XPS, providing urologists with a diverse array of options tailored to individual patient characteristics, prostate size, and specific clinical needs.

A panelist discusses how benign prostatic hyperplasia (BPH) management involves a comprehensive patient journey that encompasses initial diagnostic evaluation, tailored pharmacological interventions including α-blockers and 5-α reductase inhibitors, and a progressive treatment approach ranging from conservative drug therapy to potential surgical options based on symptom severity and patient response.